Immix Biopharma offers glimmer of hope for ALA patients

1 December 2023

Immix Biopharma (Nasdaq: IMMX) hosted a key opinion leader (KOL) event highlighting the long-term potential for NXC-201, the company’s B-cell maturation antigen (BCMA) targeting CAR-T therapy to address the fragile amyloid light chain amyloidosis (ALA) patient population.

In December 2022, Immix announced an in-licensing deal with an unnamed company for its BCMA-targeted next-generation CAR-T therapy NXC-201 (formerly HBI0101). The company also announced the formation of a new subsidiary, Nexcella, to develop and potentially commercialize NXC-201.

Commenting on this Edison Research analyst Soo Romanoff noted that this is the only CAR-T therapy in development for the treatment of relapsed/refractory ALA to her knowledge and represents a significant unmet medical need as there are only limited treatment options and no standard of care.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK